Physician profile
Leslie Carter
NPI 1730168014
$2,373.56
in general payments reported to CMS, 2019-2025
17 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.31 · 2020: $99.53 · 2021: $252 · 2022: $466 · 2023: $544 · 2024: $590 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.94 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.76 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Biowound Solutions, INC. | $191.48 | 2024-2025 | Bio-Connekt |
| Lilly USA, LLC | $174.15 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Galderma Laboratories, L.P. | $142.56 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $99.96 | 2022-2024 | Sotyktu |
| Revance Therapeutics, INC. | $71.52 | 2024 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.93 | 2021-2022 | |
| Allergan, INC. | $43.65 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $43.33 | 2022-2023 | Absorica Ld, Winlevi |
| Ucb, INC. | $35.45 | 2019-2021 | |
| Janssen Biotech, INC. | $32.36 | 2022 | |
| Genzyme Corporation | $32.19 | 2020-2025 | |
| Merz North America, INC. | $28.33 | 2020 | |
| Conmed Corporation | $19.91 | 2024 | Visiclear |
| Incyte Corporation | $18.88 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14.90 | 2021 | |
| Amgen INC. | $13.20 | 2024 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.